27 Geographic Atrophy Clinical Trials in Dallas, TX (2026)

Q: How do I join a clinical trial in Dallas?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you.

Recruiting Geographic Atrophy Studies in Dallas

NCT07700979Recruiting

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatm...

Dallas, TXPHASE3900 participantsAkeso

View Study Details

NCT05365581Recruiting

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP21...

Dallas, TXPHASE1398 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07218016Recruiting

Accelerometer Measured Early Recovery After Prolapse Surgery

The AccelERate study will evaluate the physical recovery of patients who have undergone Pelvic Organ Prolapse (POP) surgery. This will be evaluated via a self-reported recovery questionnaire completed...

Dallas, TXNA288 participantsNICHD Pelvic Floor Disorders Network

View Study Details

NCT07494318Recruiting

Advanced GastroInstestinal(GI) Surgery Training in Residency and Fellowship.

The aim of this anonymous survey is to identify who teaches GI procedures to general surgical residents during residency training and understand the need as well as desire for an Advanced Surgical GI ...

Dallas, TX260 participantsMethodist Health System

View Study Details

NCT07419334Recruiting

Study of ALK-001 on the Progression of Stargardt Disease

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (ST...

Dallas, TXPHASE3230 participantsAlkeus Pharmaceuticals, Inc.

View Study Details

NCT06022029Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expan...

Dallas, TXPHASE1168 participantsOncoNano Medicine, Inc.

View Study Details

NCT06038578Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with ...

Dallas, TXPHASE2146 participantsToray Industries, Inc

View Study Details

NCT07490132Recruiting

Endoscopic Retrograde Cholangiopancreatography

The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Ch...

Dallas, TX100 participantsMethodist Health System

View Study Details

NCT07565454Recruiting

Evaluation of Hepato-Pancreato-Biliary

Some reports cite over 80% of surgery residency graduates are seeking additional training to improve on their experiences to be ready for practice. The Fellowship Council created several fellowship tr...

Dallas, TX100 participantsMethodist Health System

View Study Details

NCT06926920Recruiting

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNB...

Dallas, TXPHASE1100 participantsGilead Sciences

View Study Details

NCT06999187Recruiting

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refra...

Dallas, TXPHASE196 participantsDren Bio

View Study Details

NCT06958796Recruiting

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late...

Dallas, TXPHASE480 participantsCamille N. Kotton, MD

View Study Details

NCT07392255Recruiting

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured a...

Dallas, TXPHASE175 participantsComplement Therapeutics

View Study Details

NCT07144137Recruiting

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

This is a non-interventional, observational study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years. This is a multi-center, non-interventional...

Dallas, TX75 participantsComplement Therapeutics

View Study Details

NCT07161544Recruiting

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the...

Dallas, TXPHASE175 participantsAAVantgarde Bio Srl

View Study Details

NCT06942572Recruiting

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This...

Dallas, TXPHASE157 participantsSplice Bio

View Study Details

NCT07230834Recruiting

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, w...

Dallas, TXPHASE154 participantsRegeneron Pharmaceuticals

View Study Details

NCT07424469Recruiting

Foregut Leaks-Role of Microbiome

Aims 1. To understand the microbial composition involved with foregut leaks 2. To define the virulence changes in the microbiota following foregut leaks 3. To identify host response mechanisms and ho...

Dallas, TXNA50 participantsBaylor Research Institute

View Study Details

NCT06445322Recruiting

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials....

Dallas, TX50 participantsAscidian Therapeutics, Inc

View Study Details

NCT06989359Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases....

Dallas, TXPHASE245 participantsADARx Pharmaceuticals, Inc.

View Study Details

NCT04422912Recruiting

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-...

Dallas, TXPHASE140 participantsCabaletta Bio

View Study Details

NCT05029999Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil...

Dallas, TXPHASE130 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT07734064Recruiting

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular d...

Dallas, TXPHASE130 participantsAstellas Institute for Regenerative Medicine

View Study Details

NCT06008275Recruiting

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial...

Dallas, TXEARLY_PHASE120 participantsBaylor Research Institute

View Study Details

NCT06467344Recruiting

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for...

Dallas, TXPHASE115 participantsAscidian Therapeutics, Inc

View Study Details

NCT07700420Recruiting

Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer

The goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction ca...

Dallas, TXPHASE115 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT07543991Recruiting

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

Giant axonal neuropathy (GAN) is a rare pediatric disorder caused by autosomal recessive mutations in the GAN gene. GAN is a multisystem, neurodegenerative disorder affecting the peripheral nervous sy...

Dallas, TXPHASE14 participantsUniversity of Texas Southwestern Medical Center

View Study Details

About Geographic Atrophy Clinical Trials in Dallas

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 27 geographic atrophy clinical trials recruiting participants in Dallas, TX. These studies are seeking a combined 3,501 participants. Research is being sponsored by Akeso, Astellas Pharma Global Development, Inc., NICHD Pelvic Floor Disorders Network and 17 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Dallas — FAQ

Are there geographic atrophy clinical trials in Dallas?

Yes, there are 27 geographic atrophy clinical trials currently recruiting in Dallas, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Dallas?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.

Are clinical trials in Dallas free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 27 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated October 15, 2026 from ClinicalTrials.gov